MX2019003888A - Compuestos de briostatina y metodos para prepararlos. - Google Patents

Compuestos de briostatina y metodos para prepararlos.

Info

Publication number
MX2019003888A
MX2019003888A MX2019003888A MX2019003888A MX2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A
Authority
MX
Mexico
Prior art keywords
bryostatin
methods
preparing
same
subject methods
Prior art date
Application number
MX2019003888A
Other languages
English (en)
Inventor
Wender Paul
Quiroz Ryan
Ho Stephen
Ryckbosch Steven
C Stevens Matthew
S Jeffreys Matthew
HARDMAN Clayton
Sloane Jack
Shimizu Akira
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2019003888A publication Critical patent/MX2019003888A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan métodos para preparar una variedad de compuestos de briostatina. Los métodos de la presente proporcionan la preparación de briostatina 1 en cantidades de múltiples gramos en una cantidad baja y sin precedentes de etapas sintéticas convergentes a partir de materiales disponibles en el mercado. Los métodos de la presente son escalables con bajos costos de materiales estimados y pueden proporcionar una cantidad suficiente de material para satisfacer los requisitos clínicos. También se proporciona una variedad de compuestos análogos de briostatina, y formas de profármaco de estos, a los que puede accederse de manera sintética a través de los métodos de la presente y composiciones farmacéuticas que los incluyen.
MX2019003888A 2016-10-05 2017-09-28 Compuestos de briostatina y metodos para prepararlos. MX2019003888A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404687P 2016-10-05 2016-10-05
PCT/US2017/054158 WO2018067382A1 (en) 2016-10-05 2017-09-28 Bryostatin compounds and methods of preparing the same

Publications (1)

Publication Number Publication Date
MX2019003888A true MX2019003888A (es) 2019-11-28

Family

ID=61831583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003888A MX2019003888A (es) 2016-10-05 2017-09-28 Compuestos de briostatina y metodos para prepararlos.

Country Status (11)

Country Link
US (3) US10947221B2 (es)
EP (1) EP3523296A4 (es)
JP (2) JP7148147B2 (es)
CN (1) CN109923110A (es)
AU (1) AU2017339786B2 (es)
CA (1) CA3038532A1 (es)
IL (2) IL265663B (es)
MX (1) MX2019003888A (es)
TW (1) TWI754676B (es)
WO (1) WO2018067382A1 (es)
ZA (1) ZA201902089B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017339786B2 (en) 2016-10-05 2021-09-02 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
US20220193029A1 (en) * 2019-05-21 2022-06-23 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds for enhancement of immunotherapy
CN112209812B (zh) * 2019-07-11 2021-12-07 中国科学院大连化学物理研究所 一种1,1-二芳基-2-烷基乙烯衍生物及其合成方法
WO2022036335A1 (en) * 2020-08-09 2022-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Organ transplant perfusion solution modifications using bryostatin-1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358711A (en) 1987-11-23 1994-10-25 Johns Hopkins University Stimulation of stem cell growth by the bryostatins
US5440055A (en) 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
CN1062866C (zh) * 1997-10-31 2001-03-07 中国人民解放军第二军医大学药学院 一种新的抗癌活性化合物草苔虫内酯
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2001040214A1 (en) * 1999-11-30 2001-06-07 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US6900339B2 (en) * 2002-04-30 2005-05-31 The University Of North Carolina At Chapel Hill Bryostatin composition and bryostatin acquisition methodologies
US8497385B2 (en) * 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009052507A1 (en) 2007-10-19 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009129361A2 (en) 2008-04-16 2009-10-22 University Of Utah Research Foundation Macrocyclic compounds and methods of making and using thereof
US8816122B2 (en) 2009-07-20 2014-08-26 The Board Of Trustees Of The Leland Stanford Junior University Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
ES2905359T3 (es) * 2012-04-26 2022-04-08 Univ Yale Moléculas de suministro de fármacos citotóxicos dirigidas al VIH (CDM-H), actividad citotóxica contra el virus de la inmunodeficiencia humana y métodos de uso
EP3105317B1 (en) 2014-02-14 2018-09-19 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
US20170239212A1 (en) 2014-08-11 2017-08-24 University Of Utah Research Foundation Bryostatin analogs and use thereof as antiviral agents
AU2017339786B2 (en) * 2016-10-05 2021-09-02 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
US11690873B2 (en) 2017-03-31 2023-07-04 Cellectis Sa Universal chimeric antigen receptor T cells specific for CD22
JP7459043B2 (ja) 2018-07-12 2024-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
US20220193029A1 (en) * 2019-05-21 2022-06-23 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds for enhancement of immunotherapy

Also Published As

Publication number Publication date
US10947221B2 (en) 2021-03-16
IL265663B (en) 2021-10-31
EP3523296A4 (en) 2020-04-01
WO2018067382A1 (en) 2018-04-12
JP2022107010A (ja) 2022-07-20
IL287119A (en) 2021-12-01
IL287119B2 (en) 2023-07-01
AU2017339786A1 (en) 2019-05-02
TWI754676B (zh) 2022-02-11
US11746105B2 (en) 2023-09-05
CN109923110A (zh) 2019-06-21
ZA201902089B (en) 2020-10-28
CA3038532A1 (en) 2018-04-12
TW201815795A (zh) 2018-05-01
US20210292309A1 (en) 2021-09-23
US20190292172A1 (en) 2019-09-26
AU2017339786B2 (en) 2021-09-02
EP3523296A1 (en) 2019-08-14
IL287119B1 (en) 2023-03-01
IL265663A (en) 2019-05-30
JP7148147B2 (ja) 2022-10-05
JP2019531295A (ja) 2019-10-31
US20240116908A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
MX2019003888A (es) Compuestos de briostatina y metodos para prepararlos.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
ZA202003022B (en) Minimal saponin analogues, synthesis and use thereof
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
BR112013026363A2 (pt) nanossuspensões de fármaco criodessecadas
MY193728A (en) Muscarinic receptor agonists
MY183927A (en) Pyridinyl and fused pyridinyl triazolone derivatives
CO6551760A2 (es) Polco de rifaximina , proceso para prepararlo y composiciones de liberación controlada que contiene dicha rifaeimina útil para obtener un efecto de larga duración
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
PH12016500988B1 (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
TN2015000542A1 (en) Novel compounds for the treatment of cancer
MX2014012164A (es) Composiciones a base de probioticos y un complejo de polen de abejas/arcilla, su preparacion y sus usos en nutricion y en terapeutica.
CL2018003587A1 (es) Composición de cal apagada en polvo altamente porosa.
UA120083C2 (uk) АНТИМЕТАСТАТИЧНІ 2H-СЕЛЕНОФЕНО[3,2-h]ХРОМЕНИ, ЇХ СИНТЕЗ ТА СПОСОБИ ЗАСТОСУВАННЯ ЦИХ АГЕНТІВ
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
IN2013MU01177A (es)
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
PH12019550098A1 (en) Nutritional composition in powder form provided in single serving capsules
MX346497B (es) Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos.
IN2014MN01492A (es)